Ratio Therapeutics has closed a $70 million series C financing round, bringing its total capital raised to over $240 million.
The Boston-based radiopharmaceutical developer will use the proceeds to advance its ATLAS study evaluating lead asset [Ac-225] RTX-2358 in advanced sarcomas and to move its next-generation radioligand therapy candidate into the clinic, Ratio said. The company also plans to expand its discovery pipeline into additional oncology targets and scale its manufacturing capabilities.
Lead investors included Duquesne Family Office and Bristol Myers Squibb, both existing investors, along with new investors Catalio Capital Management, Eli Lilly and Company, and Wasatch Group.
